Provided by Tiger Trade Technology Pte. Ltd.

ANI Pharmaceuticals

71.46
+0.76001.07%
Post-market: 71.460.00000.00%19:30 EDT
Volume:228.89K
Turnover:16.22M
Market Cap:1.64B
PE:15.74
High:71.48
Open:70.52
Low:70.07
Close:70.70
52wk High:99.39
52wk Low:69.96
Shares:22.97M
Float Shares:20.28M
Volume Ratio:0.82
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.54
EPS(LYR):3.32
ROE:20.46%
ROA:5.45%
PB:2.75
PE(LYR):21.52

Loading ...

ANI Pharmaceuticals Initiated at Hold by Canaccord Genuity

Dow Jones
·
Jul 17

U.S. Research Roundup-ibm, MSCI, US Bancorp

Reuters
·
Jul 17

Ani Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

Reuters
·
Jul 17

ANI Pharmaceuticals intends to appeal rulings in CG Oncology matter

TIPRANKS
·
Jul 17

ANI Pharma Plans Delaware Supreme Court Appeal in CG Oncology Dispute

Reuters
·
Jul 17

ANI Pharmaceuticals - Trial Court Denies ANI Pharmaceuticals' Motion for New Trial and Judgment

THOMSON REUTERS
·
Jul 17

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

THOMSON REUTERS
·
Jul 17

ANI Pharmaceuticals Inc: Continue to Seek to Recover Value of Assets it Sold to CG Oncology in 2010

THOMSON REUTERS
·
Jul 17

ANI Pharmaceuticals initiated with a Hold at Canaccord

TIPRANKS
·
Jul 17

ANI Pharmaceuticals SVP, General Counsel Meredith Cook Disposes of 500 Common Shares for $40,920

Reuters
·
Jul 15

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 14

Buzz-ani Pharma's Eye Implant Meets Main Goals in Eye Disease Trial

Reuters
·
Jul 13

ANI Says Phase 4 Chronic Non-Infectious Uveitis Trial Met Primary Endpoints

MT Newswires Live
·
Jul 13

ANI Pharmaceuticals Announces Positive Six-month Topline Data from the Phase 4 Open-label, Single-arm Synchronicity Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-infectious Uveitis

THOMSON REUTERS
·
Jul 13

ANI Pharmaceuticals - Synchronicity Trial Meets Both Co-primary Endpoints at 6 Months

THOMSON REUTERS
·
Jul 13

ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity?

Simply Wall St.
·
Jul 11

ANI Pharmaceuticals Price Target Maintained with a $124.00/share by Guggenheim

Dow Jones
·
Jul 10

ANI Pharma SVP, CFO Stephen P. Carey Disposes of 3,313 Common Shares Worth $284,918

Reuters
·
Jul 07

ANI Pharma SVP, CFO Stephen P. Carey Disposes of 2,850 Shares for $239,742‬

Reuters
·
Jul 01

ANI Pharma Sr. VP, General Counsel Meredith Cook sells 500 common shares worth $41,015

Reuters
·
Jun 16